Table 1 Baseline characteristics according to anti-platelet approach in AIS Patients before and after PSM
From: Association between tirofiban monotherapy and efficacy and safety in acute ischemic stroke
Before Matching | After Matching | |||||
|---|---|---|---|---|---|---|
Dual antiplatelet (n = 169) | Tirofiban (n = 86) | ASD, % | Dual antiplatelet (n = 50) | Tirofiban (n = 50) | ASD, % | |
Age, y, mean (sd) | 72.4 (10.1) | 72.4 (10.3) | 0.4 | 70.1 (11.2) | 70.7 (10.9) | 5.4 |
Female, no. (%) | 72 (42.6) | 40 (46.5) | 7.9 | 23 (46) | 22 (44) | 4.0 |
Smoke ever, no. (%) | 30 (17.8) | 24 (27.9) | 24.4 | 8 (16) | 8 (16) | 0 |
Premorbid mRS, mean (sd) | 0.4 (0.7) | 0.4 (0.7) | 2.0 | 0.5 (0.8) | 0.5 (0.8) | 5.2 |
Stroke etiology | ||||||
Large artery atherosclerosis | 133 (78.7) | 74 (86.0) | 22.10 | 42 (84) | 41 (82) | 5.6 |
Cardioembolism | 3 (1.8) | 2 (2.3) | 1 (2) | 1 (2) | ||
Other | 33 (19.5) | 10 (11.6) | 7 (14) | 8 (16) | ||
ASPECTS, mean (sd) | 7.9 (2.4) | 8.3 (1.8) | 22.3 | 8.2 (1.9) | 7.9 (2) | 15.2 |
Admission SBP, mm Hg, mean (sd) | 155.4 (28.6) | 141.9 (23.5) | 51.7 | 147 (27.9) | 143.9 (23.3) | 12.2 |
Prior use of IV thrombolysis, no. (%) | 11 (6.5) | 7 (8.1) | 6.3 | 4 (8) | 5 (10) | 7.0 |
Endovascular treatment, no. (%) | 28 (16.6) | 13 (15.1) | 4.0 | 7 (14) | 8 (16) | 5.6 |
NIHSS score prior to treatment, mean (sd) | 8 (3.6) | 11.7 (5.5) | 80.0 | 10.1 (3.6) | 10 (5.1) | 2.7 |
Medical history | ||||||
Hypertension, no. (%) | 137 (81.1) | 18.7 | 18.7 | 38 (76) | 38 (76) | 0 |
Diabetes, no. (%) | 25 (14.8) | 10.2 | 10.2 | 7 (14) | 8 (16) | 5.6 |
Hyperlipidemia, no. (%) | 11 (6.5) | 14.2 | 14.2 | 2 (4) | 4 (8) | 16.9 |
Atrial fibrillation, no. (%) | 19 (11.2) | 4.8 | 4.8 | 4 (8) | 5 (10) | 7.0 |
Coronary disease | 56 (33.1) | 22.1 | 22.1 | 12 (24) | 11 (22) | 4.8 |
Workflow, median (IQR), min | ||||||
onset to admission, h, mean (sd) | 7.5 (3.9) | 6.1 | 6.1 | 8.1 (4.5) | 8 (3.7) | 2.4 |
onset to treatment, h, mean (sd) | 9.8 (4.2) | 13.8 | 13.8 | 10.7 (5) | 10.3(4.7) | 6.4 |